Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients

Table 3 Safety profile of triple therapy: Severe adverse events grade 3 or 4 n (%)

	Overall patients(n = 124)	Telaprevir(n = 89)	Boceprevir(n = 35)	P valueunivariateanalysis
Premature discontinuation due to SAE	11 (8)	10 (11.2)	1 (2.9)	0.178
Death	0	0	0	-
Severe adverse events grade 3/4	63 (50.8)	46 (51.7)	17 (48.6)	0.75
Infection	4 (3.2)	3 (3.4)	1 (2.9)	1
Liver decompensation	2 (1.6)	2 (2.2)	0	1
Fatigue	3 (2.4)	3 (3.4)	0	0.558
Skin rash	2 (1.6)	2 (2.2)	0	1
Kidney failure	1 (0.8)	1 (1.1)	0	1
Digestive adverse events	1 (0.8)	1 (1.1)	0	1
Thromboembolic events	1 (0.8)	1 (1.1)	0	1
Anemia	18 (14.5)	16 (18)	2 (5.7)	0.081
Neutropenia	21 (16.8)	14 (15.7)	7 (20)	0.568
Thrombocytopenia	42 (33.6)	32 (36)	10 (28.6)	0.434
Erythropoietin use1	65 (52)	45 (90)	20 (57.1)	0.473
Blood transfusion1	17 (13.6)	15 (16.7)	2 (5.7)	0.149

Only severe adverse events (SAEs) of grade 3 or 4 were reported in the table. SAEs were known for 124 patients.

¹Erythropoietin use and blood transfusions were analyzed among the 125 patients. A single subject might have several severe adverse effects.